38.06
-2.4(-5.93%)
Currency In USD
| Previous Close | 40.46 |
| Open | 40.91 |
| Day High | 40.91 |
| Day Low | 38.03 |
| 52-Week High | 41.09 |
| 52-Week Low | 8.24 |
| Volume | 949,908 |
| Average Volume | 1.53M |
| Market Cap | 2.52B |
| PE | -10.18 |
| EPS | -3.74 |
| Moving Average 50 Days | 24.77 |
| Moving Average 200 Days | 16 |
| Change | -2.4 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $2,063.99 as of October 04, 2025 at a share price of $38.06. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $2,742.07 as of October 04, 2025 at a share price of $38.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to tar
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
GlobeNewswire Inc.
Sep 05, 2025 1:00 PM GMT
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and par
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease